Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
By P. Poole‐Wilson, K. Swedberg, J. Cleland, A. Di Lenarda, P. Hanrath, M. Komajda, J. Lubsen, B. Lutiger, M. Metra, W. Remme and 3 more. The Lancet, 2003
1,826 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine
View Paper: https://www.semanticscholar.org/paper/fab668e00037d7052bf4494f4bb39ccbe1ea837a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- J. Cleland
- Gerasimos Filippatos
- L. Tavazzi
- S. Thompson
- Jeroen J. Bax
- Helmut Baumgartner
- Rick A. Nishimura
- Paulus Kirchhof
Citations in the corpus
- Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). (2005, background): “Previous studies have raised the possibility that beta-blockers in heart failure need to be evaluated separately and the effects of one cannot be extrapolated to another.(29,30) It has been estimated that the probability of receiving beta-blocker therapy is substantially lower in the elderly(31,32) ”
- ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit (2006, positive): “In large HF trials (COMET [Carvedilol Or Metoprolol European Trial], Val-HeFT [Valsartan Heart Failure Trial]), AF was a strong independent risk factor for mortality and morbidity.(20,21) HF promotes AF, AF aggravates HF, and individuals with either condition who develop the alternate condition shar”